Development and validation of a clinical index for assessment of long‐term damage in juvenile idiopathic arthritis

Abstract

Objective. To develop and validate a clinical measure of articular and extraarticular damage in patients with juvenile idiopathic arthritis (JIA).Methods. The Juvenile Arthritis Damage Index (JADI), which is derived from physical examination and a brief review of the patient's clinical history, is composed of 2 parts: assessments of articular damage (JADI-A) and extraarticular damage (JADI-E). Instrument validation was accomplished by evaluating 158 JIA patients with disease duration of at least 5 years, seen consecutively over 21 months. The instrument's feasibility, face and content validity, construct and discriminative ability, internal consistency, and interrater reliability were examined.Results. Among the 158 JIA patients, 47% and 37% had articular and extraarticular damage, respectively. The JADI was found to be feasible and to possess both face and content validity. Conclusion. The JADI exhibited good reliability, construct validity, and discriminative ability and is therefore a valid instrument for the assessment of long-term damage in patients with JIA, in the context of both clinical management and research settings.

Proxy‐reported health‐related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study

“…The assessment of children with juvenile idiopathic arthritis (JIA) has been traditionally focused on disease-centered outcomes, such as disease activity, clinical remission, articular and extraarticular damage, and results of laboratory indicators of systemic inflammation (1)(2)(3). Because JIA influences virtually all aspects of the child's life and his or her family (4), it is increasingly recognized that a complete assessment of the disease requires the evaluation of healthrelated quality of life (HRQOL), which is a multidimensional concept that incorporates measures of physical symptoms, functional status, and disease impact on psychological and social functioning (5,6).…”

Current outcome of patients with juvenile idiopathic arthritis: Clinical assessment, Disease activity, Functional ability and Articular and Extra-Articular damage.

“…JAD-A includes 36 joints or joint groups which are assessed for the presence of damage, and the damage presence in each joint is scored on a 3 point scale (where 0: no damage, 1: partial damage, and 2: sever damage, ankyloses or prosthesis).joint damage that is present for at least 6 months and not duo to currently active arthritis was considered as severe damage [14].…”

“…Each item is scored as either 0 or 1 according to absent or present of damage respectively. Ocular damage was scored 2 for each eye when the patient had ocular surgery and score 3 when the patient has developed legal blindness [14].…”

“…JADI is the instrument that consists of 2 parts; articular and extra-articular ([JADI-A and JADI-E]), and considered as a reliable tool for measuring long-term outcome in large cohorts and is likely increase the current understanding of the nature history of different ILAR category [4].…”

Juvenile idiopathic arthritis in adult patients: an analysis of clinical data

“…Окремо оцінювали клінічний стан на момент огляду в дорос-лому віці з врахуванням активності захворювання за JADAS, DAS28, загального стану пацієнтом за ВАШ при ЮІА в дорослому віці, оцінка якості життя за SF-36 та рівень порушення функціональної актив-ності за допомогою анкети Health Assessment Questionnaire (HAQ), оцінка психологічного стану за до-помогою опитувальників шкали тривоги Бека, само-оцінки тривоги, НАМ-А, самооцінки депресії, шкали депресії PHQ-9, та оцінка серцево-судинного ризику з корекцією згідно EULAR-рекомендацій оцінки № 6(14)2017 серцево-судинного ризику у пацієнтів з запальними захворюваннями суглобів [7]. Віддалені наслідки ЮІА оцінювалися за індексом суглобових (JADI-A) та позасуглобових (JADI-E) уражень [8]. Всім паці-єнтам проводились загальноклінічні аналізи крові натще та оцінювали наступні показники: загальний аналіз крові та ШОЕ поточною цитофлуориметрією з використанням лазерних напівпровідників і гідроди-намічного фокусування (Sysmeх ХТ-2000і, ХЕ-2100; Япониія), С-реактивний білок (СРБ) кількісно мето-дом латекс-турбидиметричний (Cobas 6000; Roche Diagnostics, Швейцарія), загальний холестерин та ліпопротеїди низької щільності (ЛПНЩ) фермента-тивно-колориметричним методом (Cobas 6000; Roche Diagnostics, Швейцарія).…”